Host airway epithelial cell genome

The host airway epithelial cell genome refers to the complete set of genetic material within the cells lining the respiratory tract, serving as a critical interface between the host and the external environment (Crystal et al., 2008, Nature). These cells are central to the pathogenesis of various respiratory diseases, including cystic fibrosis, where mutations in the CFTR gene lead to defective ion transport (Cutting, 2015, Nature Reviews Genetics). While the genome itself is not a discrete therapeutic target, specific loci within it are the focus of gene therapy and CRISPR-based editing efforts aimed at correcting hereditary defects or modulating inflammatory responses (Griesenbach & Alton, 2015, Journal of Internal Medicine). In the context of viral infections like SARS-CoV-2, the host genome's expression profile determines cellular susceptibility and the magnitude of the immune response (Ziegler et al., 2020, Cell). Pharmacological strategies often target the protein products of this genome, but emerging technologies seek to interact directly with DNA sequences to provide long-term therapeutic benefits (Yan et al., 2019, Molecular Therapy). Safety concerns regarding genomic interventions include off-target mutations and potential oncogenesis due to unintended genetic alterations (Fu et al., 2013, Nature Biotechnology).

Other names

Respiratory epithelial genomeAirway epithelium DNALung cell genome

Direct modification of genomic DNA sequences or the introduction of exogenous genetic material to correct mutations or modulate gene expression.